Number of individuals with eating difficulties (8 days after administration); duration of eating difficulties · Children and young adults under 25 years with primary herpetic gingivostomatitis (with or without herpes labialis)
Systemic oral acyclovir led to lower number of individuals with eating difficulties (8 days after… compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Difficulty in drinking (number with drinking difficulties) · Children and young adults under 25 years with primary herpetic gingivostomatitis (with or without herpes labialis)
Systemic oral acyclovir led to lower number of individuals with drinking difficulties (8 days after… compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Number of individuals admitted to hospital after administration · Children and young adults under 25 years with primary herpetic gingivostomatitis (with or without herpes labialis)
Systemic oral acyclovir showed no clear difference in number of individuals admitted to hospital after administration compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Duration of fever · Children and young adults under 25 years with primary herpetic gingivostomatitis (with or without herpes labialis)
1 finding from 1 review
Perceptual speech assessment: residual post-operative velopharyngeal insufficiency · Children or adolescents aged 3 years or older with velopharyngeal insufficiency (VPI) associated with non-syndromic submucous cleft palate
1 finding from 1 review
Five (14%) of the participants in group 1 (MIPP) and four (11%) in group 2 had residual post-operative velopharyngeal insufficiency, P > 0.05. The report provided no details on post-operative speech assessment other…
1 study · 72 participants
GRADE not reported
Mean time to resolution of pain · Children and young adults under 25 years with primary herpetic gingivostomatitis (with or without herpes labialis)
1 finding from 1 review
Amir 1997b: no data available. Ducoulombier 1988: time to resolution of pain, acyclovir (1 day=1, 2 days=1, 3 days=3, 4 days=3, 5 days=1, persistent=0) vs placebo (1 day=0, 2 days=0, 3 days=1, 4 days=2, 5 days=4,…
1 study · 18 participants
GRADE not reported
Systemic fungal infection · Patients with cancer receiving chemotherapy and/or radiotherapy
Antifungal drugs partially absorbed from GI tract (miconazole,… showed no clear difference in systemic fungal infection compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Oral candidiasis (present) · Patients with cancer receiving chemotherapy and/or radiotherapy
Antifungal drugs not absorbed from GI tract showed no clear difference in oral candidiasis (present) compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Oral candidiasis (present) · Patients with cancer receiving chemotherapy and/or radiotherapy
Amphotericin B showed no clear difference in oral candidiasis (present) compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Empirical antifungal treatment · Patients with cancer receiving chemotherapy and/or radiotherapy
Itraconazole showed no clear difference in empirical antifungal treatment compared with fluconazole; GRADE not reported.
1 finding from 1 review
Systemic fungal infection · Patients with cancer receiving chemotherapy and/or radiotherapy
Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole,… showed no clear difference in systemic fungal infection compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Relief of dysphagia · Patients with cancer receiving chemotherapy and/or radiotherapy
The review found no eligible studies for this question.
1 finding from 1 review
Empirical antifungal treatment · Patients with cancer receiving chemotherapy and/or radiotherapy
Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole,… led to lower empirical antifungal treatment compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Oral candidiasis (present) · Patients with cancer receiving chemotherapy and/or radiotherapy
1 finding from 1 review
Oral candidiasis (present) · Patients with cancer receiving chemotherapy and/or radiotherapy
Norfloxacin plus amphotericin B showed no clear difference in oral candidiasis (present) compared with amphotericin B; GRADE not reported.
1 finding from 1 review
Length of hospital stay · Patients with cancer receiving chemotherapy and/or radiotherapy
The review found no eligible studies for this question.
1 finding from 1 review
Death associated with fungal infection · Patients with cancer receiving chemotherapy and/or radiotherapy
Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole,… showed no clear difference in death associated with fungal infection compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Systemic fungal infection · Patients with cancer receiving chemotherapy and/or radiotherapy
Itraconazole showed no clear difference in systemic fungal infection compared with fluconazole; GRADE not reported.
1 finding from 1 review
Oral candidiasis (present) · Patients with cancer receiving chemotherapy and/or radiotherapy
1 finding from 1 review
Oral candidiasis (present) · Patients with cancer receiving chemotherapy and/or radiotherapy
Thymostimulin showed no clear difference in oral candidiasis (present) compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review